Acoustic Neuroma Market Research Report-
By Type (Unilateral, Bilateral) By Diagnosis (Audiometry,
Electronystagmography, MRI) By Treatment (Monitoring, Surgery, Radiaotherapy,
Supportive Therapy) By Drug Class, By End User– Global Forecast till 2023
The global acoustic
neuroma market is expected to grow at a CAGR of approximately 7.6% during
the forecast period 2017-2023.
Market Scenario
Acoustic
neuromas also known as vestibular schwannomas, usually grows slowly over a
period of years. Usually they do not invade the brain, but can push on it as
they grow. As the tumor grows, they press the nearby cranial nerves that control
the muscles enabling facial expression and sensation. If the tumor becomes
large enough to press on the brain stem or cerebellum, it can be deadly. They
account for almost 8% of all tumors inside the skull. The prevalence rate is 1
out of every 100,000 individuals per year.
An acoustic
neuroma is a non-cancerous (benign) growth that develops on the 8th cranial
nerve (vestibulocochlear nerve), it connects the inner ear with the brain and
has two different parts. One part is involved in transmitting sound and the
other sends balance information to the brain.
Acoustic neuromas are mainly categorized into
unilateral and bilateral vestibular schwannomas. Unilateral affect only one ear
and bilateral vestibular schwannomas affect both hearing nerves and are usually
associated with some genetic disorder. More than half of the affected
individuals have inherited the disorder from an affected parent. Several new
drugs are launched by the key players which grants various opportunities for
the global acoustic neuroma market.
Usually these
neuromas are rare. Globally around 1-20 people in every million are diagnosed
each year with an acoustic neuroma. Acoustic neuromas account for about 6 cases
in every 100 patients with brain tumours. They are more common in middle-aged
adults and are rare in children. Furthermore, these neuromas seem to be
more common in women than in men. Acoustic neuromas tend to affect adults aged
30 to 60 and usually have no obvious cause, although a small number of cases
are the result of a genetic condition called neurofibromatosis type 2 (NF2).
The gadolinium
enhanced magnetic resonance imaging (MRI) is the gold standard for diagnosis of
vestibular schwannoma yet several examinations may arise suspicion of
vestibular schwannomas. According to a patient survey held by the Acoustic
Neuroma Association, in 2012, it was reported that after surgical treatment of
acoustic neuroma more than 35% patients suffered a headache depending on the
type of surgical approach, technique used and the time since surgery.
Top Key Acquisitions
Many new companies
have jumped into the market in order to make the most out of the opportunities.
Companies are implementing the strategies of mergers and acquisitions with
other players.
Some of key
the players in the global acoustic neuroma market are GE Healthcare (U.S.),
Siemens Healthcare(U.S.), Philips Healthcare (U.S.), Shimadzu Corporation
(Japan), Toshiba Medical Systems Corporation (Japan), F. Hoffmann-La Roche Ag,
Merck & Co., Inc., Novartis AG, Pfizer Inc., and others
Segmentation
The acoustic
neuroma is segmented on the basis of type, diagnosis, drug class, treatment,
and end-users.
On the basis
of type, the market is segmented into unilateral vestibular schwannomas and
bilateral vestibular schwannomas.
On the basis
of diagnosis, the market is segmented into hearing test (audiometry),
electronystagmography, magnetic resonance imaging (MRI), and others.
On the basis
of end-user, the market is segmented into hospitals, diagnostic centers, academic
and research institutes, and others.
On the basis
of drug class, the market is segmented into anticonvulsants, corticosteroids,
osmotic diuretics and pain killers.
On the basis
of treatment, the market is segmented into monitoring, surgery, radiation
therapy, supportive therapy and others. The radiation therapy is sub segmented
stereotactic radiotherapy, proton beam therapy. Surgery is sub segmented
radiosurgery, craniotomy, and microsurgery removal
Regional
Analysis
The global
acoustic neuroma market consists of countries namely America, Europe, Asia
Pacific, and the Middle East.
North America
is projected to hold the largest share of the global acoustic neuroma market
due to presence of huge numbers of key players supporting research and
development for developing novel therapies, large base of diagnostic centers
and greater emphasis on disease prevention and wellness by governments. Along
with that healthcare facilities in the U.S. are gradually moving from treatment
to wellness, so the prevention and early detection of disease is critical.
Approximately 2,000 to 3,000 cases are diagnosed each year with acoustic
neuroma in the United States (6 to 9 per million persons).
The European
acoustic neuroma market hold the second largest market as it witness rapid
growth. According to NHS U.K, an acoustic neuroma can occasionally return after
treatment. This is thought to happen to around 1 in every 20 people who have
had surgical removal.
Asia Pacific
is expected to be the most promising markets for acoustic neuroma in the near
future The Middle Eastern region is expected to grow at a faster rate due to
the factors such as the extensive development of health care infrastructure and
growing emphasis on research and development in the health care sector.
Browse more
Medical Devices Reports @ https://www.marketresearchfuture.com/categories/medical-devices-market-report
No comments:
Post a Comment